SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The MELANIA token continues to face intense skepticism from the community, with many investors labeling it a pump-and-dump scheme following its severe decline from peak valuations. Market participants are actively debating the token's lack of utility and transparency, frequently contrasting its performance with mainstream cryptocurrencies while expressing frustration over the losses linked to the broader Trump-affiliated crypto ecosystem.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

The RAGE crypto community is rallying behind the project with intense conviction, emphasizing long-term 'bagworking' and the creation of OG-style rage comics to drive mindshare. Investors are actively pushing to secure a top market position while warning against copycat tickers and urging others to join their grassroots effort before a potential breakout.

SharonAI Holdings, Inc. engages in providing high-performance computing (HPC), artificial intelligence (AI), and cloud GPU compute infrastructure technologies. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI Holdings is capturing investor interest following a strategic partnership with World Wide Technology and aggressive long-term capacity expansion plans. The community is heavily focused on the stock's potential for a significant short squeeze driven by a thin float, sparking intense debate regarding its volatility and future trajectory.

Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.

Celcuity Inc

Celcuity is trending following the publication of positive Phase 3 VIKTORIA-1 trial data, which demonstrated significant survival benefits for its investigational breast cancer drug, gedatolisib. Investors are actively discussing the potential for an accelerated FDA approval timeline, the strategic implications of a recent capital raise, and the stock's long-term value as a potential first-in-class standard of care.

Fabrinet engages in the provision of optical packaging and electronic manufacturing services to original equipment manufacturers. The firm's engineering services include process design, failure analysis, reliability testing, tooling design, and real-time traceability system. Its manufacturing operations offer sensors, subsystems, customized optics, and optical modules and components. The company was founded by David Thomas Mitchell on August 12, 1999 and is headquartered in George Town, Cayman Islands.

Fabrinet

Fabrinet is currently trending as investors closely monitor its role in the AI-driven data center and optical packaging sector, with community sentiment divided between excitement over long-term growth and caution regarding valuation and potential supply chain shifts. Discussion is heavily focused on the company's recent earnings performance, its strategic importance as a manufacturer for major tech partners, and its ability to sustain momentum amid sector volatility.

Ecopetrol SA engages in the exploration, development, and production of crude oil and natural gas. It operates through the following segments: Exploration and Production, Transportation and Logistics, and Refining and Petrochemicals. The Exploration and Production segment deals with oil and gas exploration and production activities. The Transportation and Logistics segment comprises of pipelines and other transportation activities. The Refining and Petrochemicals segment involves in refining activities and its products include motor fuels, fuel oils, and petrochemicals. The company was founded in 1948 and is headquartered in Bogota, Colombia.

Ecopetrol SA - ADR

Ecopetrol SA

Ecopetrol is trending as investors weigh its potential as an undervalued energy play with a strong dividend yield against ongoing geopolitical risks in Colombia and shifting global oil market dynamics. The community is actively debating the stock's long-term outlook, focusing on the company's operational resilience and the impact of political developments on its future growth.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is gaining institutional momentum ahead of its upcoming earnings as investors rotate out of technology and into resilient healthcare names, while the company leverages a robust portfolio of mature drugs and late-stage pipeline assets to navigate competitive pricing pressures. Market participants are closely watching the company's capital allocation strategy and manufacturing expansion efforts, which are being bolstered by favorable policy developments and a strengthening competitive position in the cardiovascular and inflammatory disease markets.

Barclays Bank Plc engages in providing commercial banking services. It offers personal, premier, business, and corporate banking products and services to its customers. Its services include current accounts, savings, investments, mortgages, loans, insurance, credit cards, and online banking. The company was founded on October 4, 1971 and is headquartered in London, the United Kingdom.

Barclays Bank PLC - iPathÂ® Series B S&P 500Â® VIX Short-Term FuturesTM ETN

iPath S&P 500 VIX Short-Term Futures ETN

Investors are closely watching the iPath S&P 500 VIX Short-Term Futures ETN (VXX) as market participants debate whether extreme volatility-shorting behavior signals a major market peak or continued complacency. Community discussion is currently fixated on whether the recent compression in volatility indices, coupled with macroeconomic uncertainty, is setting the stage for a significant capitulatory event or another aggressive melt-up.

OppFi, Inc. is a tech-enabled, mission-driven specialty finance platform, which engages in the provision of community banks to extend credit access to everyday Americans. It supports consumers, who are turned away by mainstream options, to build better financial health, through transparency, responsible lending, financial inclusion, and an excellent customer experience. The company was founded by Todd G. Schwartz and Theodore Schwartz in 2012 and is headquartered in Chicago, IL.

OppFi Inc - Ordinary Shares - Class A

OppFi Inc

OppFi Inc. is trending as investors weigh strong operational results, including record quarterly profitability and raised guidance, against concerns regarding the company's complex Up-C ownership structure. Community sentiment remains polarized, with many highlighting the stock's discounted valuation and aggressive share buybacks as a bullish setup, while others caution that the conversion of legacy ownership units continues to complicate GAAP earnings and long-term price performance.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF (SHLD) is capturing significant attention as investors double down on defense exposure, driven by record-high global military spending and increasing geopolitical instability. The community remains highly bullish, frequently debating the ETF's strategic inclusion of international and AI-focused defense contractors compared to traditional US-only aerospace and defense peers.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Shkreli had earlier announced an investment in the company and expressed his desire to become the CEO.</li><li>Trading was twice halted within the first 15 minutes of the market opening.</li><li>QCLS said Martin Shkreli will add industry connections, early-stage growth expertise, and financial innovation insight as it scales its next-gen computing platform.</li></ul>Shares of Q/C Technologies, Inc. (QCLS) crashed over 13% in volatile trading on Tuesday, after the company appointed Martin Shkreli as a strategic advisor.Earlier in the session, <a href="https://stocktwits.com/symbol/QCLS">QCLS</a> had climbed more than 11%. However, trading was twice halted within the first 15 minutes of the market opening.<h2 class="st-heading-2">Shkreli Appointed Advisor</h2>The company said former hedge fund manager and pharmaceutical executive Martin Shkreli will bring industry connections, early-stage growth experience, and insights into financial innovation as it scales its next-generation computing platform.Shkreli joins an advisory roster that already includes noted technologist James Altucher, strengthening Q/C's expertise across computing, AI, and blockchain.“I'm convinced that the next leap in frontier computing is optical, not purely quantum. Q/C’s ‘quantum class’ technology approach bridges frameworks, offering the potential for extraordinary performance and efficiency gains,” Shkreli said.Q/C’s flagship QC-LPU100 laser processing units use light rather than electrical signals to deliver efficient, high-performance computing. In partnership with Lightsolver, the company is adapting its technology for real-world blockchain applications.In a post on X last week, Shkreli announced an investment in the company and expressed his desire to become the CEO. Shkreli also added that the near-term target for the stock was $100.<stembedurl>https://x.com/MartinShkreli/status/1996225504416792760</stembedurl>The stock surged 38% that day, followed by a 48% jump in the following session.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the intraday decline, retail sentiment on Stocktwits remained in the ‘extremely bullish’ territory, accompanied by ‘extremely high’ message volumes. QCLS was among the top trending tickers on Stocktwits.One user on the platform expects the stock to climb to $11. It is currently trading at $7.7.<stembedurl>https://stocktwits.com/PoplarAve/message/638553929</stembedurl>&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/what-is-purchasing-manager-s-index/cLIrUN7REZr">What Is Purchasing Manager’s Index?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Artistic representation of a trending chart.

‘Pharma Bro’ Martin Shkreli Becomes Strategic Advisor To This Company – Stock Slumps 13% In Volatile Session

QCLS stock had surged 11% before declining 13% in the first half hour of trade on Wednesday.

Equity

<ul class="summary-bullets"><li>Shkreli said that he would join the company as CEO if President Trump allowed it.</li><li>QCLS was formerly known as TNF Pharmaceuticals and announced a name change in September 2025 as it pivoted to become a quantum-class computing company.</li></ul>Q/C Technologies Inc. (QCLS) shares soared over 60% on Thursday, extending Wednesday’s gains as American pharma investor Martin Shkreli announced that he had purchased the company’s shares.“We bought a photonic/optical computing stock: $QCLS. I'm convinced that the answer to frontier computing is optical, not quantum. we're calling it "quantum class" so investors understand it,” Shkreli said in a post on X. He also added that he would join the company as CEO if President Trump allowed it.Shkreli also noted that his near-term target on the stock is $100. Currently, QCLS shares are trading around $7.<figure class="image"><a class="st-link-external" href="https://x.com/MartinShkreli/status/1996225504416792760" target="_blank" rel="noopener noreferrer nofollow"><img style="aspect-ratio:1171/488;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_9_37_05_PM_png_4d4226b6e5.webp" alt="Shkreli said on X that he bought QCLS." width="1171" height="488"></a></figure><h2 class="st-heading-2"> Quantum Leaps</h2>Shkreli said that photonic technology delivers on the promise of quantum computing with realistic capabilities, while matrix multiplication could be far faster than GPUs.QCLS was formerly known as TNF Pharmaceuticals, Inc. (TNFA). The company announced a name change in September to represent its strategic pivot from pharmaceuticals to quantum-class computing.In October, the company obtained exclusive global digital rights to LightSolver’s laser processing unit (LPU) that can be used in the cryptocurrency verticals.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for the stock was ‘extremely bullish’ while message volume jumped to ‘extremely high’ at the time of writing. The stock was also the second-most-trending ticker on the platform.<figure class="image"><img style="aspect-ratio:1281/156;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_04_at_10_04_48_PM_png_ecefdba5d2.webp" alt="On Stocktwits, retail sentiment was ‘extremely bullish’ while message volume jumped to ‘extremely high’." width="1281" height="156"></figure>One user highlighted their positive take on the stock.<stembedurl>https://stocktwits.com/BullishBee/message/638169244</stembedurl>Another user noted that the stock was ready for another rally.<stembedurl>https://stocktwits.com/RM7391/message/638168492</stembedurl>Shares of QCLS are down over 98% year-to-date.Also Read: <a href="https://stocktwits.com/news-articles/markets/equity/brr-stock-jumps-after-ceo-pompiliano-accepts-1-salary-with-stock-incentives/cLIiP4NREjB">BRR Stock Jumps After CEO Anthony Pompiliano Accepts $1 Salary With Stock Incentives</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.&nbsp;

Quantum Computing, Quantum Physics, Quantum mechanics, Science, Technology. (Representative image courtesy of Just_Super via Getty Images)

Why Did QCLS Stock Surge Over 60% Today?

QCLS shares rallied after American pharma investor Martin Shkreli said on X that he had bought the stock, giving it a near-term price target of $100. 

<ul class="summary-bullets"><li>The stake sale comes on the heels of the company increasing its stake in TNF Pharmaceuticals in September by an additional $3 million.&nbsp;</li><li>PharmaCyte said that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.&nbsp;</li><li>The company said that monetizing its stake in Femasys will help strengthen its financial position.</li></ul> PharmaCyte Biotech, Inc. (PMCB) said on Tuesday that it sold its stake in Femasys Inc. (FEMY), thereby increasing its cash and marketable securities to about $20 million.The company had cash and marketable securities of only about $13.3 million as of the end of July. The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.pharmacyte.com/press-releases/detail/319/pharmacyte-biotech-successfully-monetizes-femasys-stake">said</a> that monetizing its stake in Femasys will help strengthen its financial position.Shares of <a href="https://stocktwits.com/symbol/PMCB">PMCB </a>traded 25% higher at the time of writing.<h2 class="st-heading-2">PharmaCyte’s Financial Position</h2>CEO Josh Silverman stated that the successful monetization of the Femasys position demonstrates the effectiveness of the strategic and disciplined capital allocation approach. “We are committed to deploying shareholder capital intelligently, balancing near-term returns with opportunities that can deliver sustained value creation,” he said.Overall, PharmaCyte now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash. The company highlighted its low stock price below $1 and added that it plans to continue pursuing value-accretive investment opportunities and disciplined operational management.The stake sale comes on the heels of the company increasing its stake in Q/C Technologies, formerly known as TNF Pharmaceuticals, in September by an additional $3 million.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around PMCB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.A Stocktwits user opined that the news shows the company has ways to generate cash without doing share offerings.<stembedurl>https://stocktwits.com/MadBat/message/637404061</stembedurl>Another expects the stock to cross the $1 threshold.<stembedurl>https://stocktwits.com/cbt2020/message/637412358</stembedurl>PMCB stock fell 48% this year and by about 53% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/nio-stock-slips-after-q4-revenue-guidance-disappoints/cL52NcEREgI">Nio Stock Slips After Q4 Revenue Guidance Disappoints</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Rising stock market chart on a trading board background.

PMCB Stock Jumps 25% After Company Sells Stake In Femasys

PharmaCyte noted that it now has approximately $25 million in marketable securities, in addition to roughly $20 million in cash.

Q/C Technologies, Inc. (QCLS) stock surged 15% in the premarket session and became the top trending ticker among equities on Stocktwits on Friday morning. The stock is on its way toward the $6 mark, last seen in August this year.The stock has garnered significant retail attention in recent days following the firm's announcement of a shift in focus to high-performance computing tailored for the cryptocurrency space. Momentum around quantum computing, triggered by recent&nbsp;advancements in both quantum hardware and software, along with efforts to build more powerful quantum machines, also helped build interest around the stock.Formerly known as&nbsp;TNF Pharmaceuticals Inc., the company changed its name to Q/C Technologies to reflect its focus towards quantum-class computing, catering to crypto and blockchain applications.Retail sentiment around&nbsp;<a href="https://stocktwits.com/symbol/QCLS">Q/C Technologies' stock</a>&nbsp;jumped to ‘extremely bullish’ from ‘neutral’ territory the previous day. Message volume improved to ‘extremely high’ from ‘low’ levels in 24 hours.&nbsp;On September 24, the company stated that it secured exclusive worldwide rights to a laser-based processor developed by LightSolver. This light-speed laser processing unit (LPU) boosts computing by leveraging the speed and efficiency of photons over traditional semiconductor methods.LightSolver’s LPU is said to reduce power usage by up to 90% while outperforming current graphics processing units (GPUs) and quantum computing platforms in both speed and reliability. In addition to performance improvements, the system provides enhanced security for blockchain networks, a feature of growing importance for decentralized finance and cryptocurrency protocols.Q/C Technologies’ stock has lost over 96% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/howard-lutnick-pushes-back-on-nvidia-uae-ai-chip-deal-report-says/chCu4zUR3fi">Howard Lutnick Pushes Back On Nvidia’s Multi-Billion-Dollar UAE AI Chip Deal? Report Says Delay Leaves Jensen Huang Frustrated</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

A quantum computer being built by the start-up IQM Germany is located in a data center.

QCLS Stock Surges 15% In Pre-Market Today, Inches Closer To $6 Mark 

The stock has garnered significant retail attention in recent days following the firm's announcement of a shift in focus to high-performance computing tailored for the cryptocurrency space. 

Q/C Technologies, Inc. engages in the provision of energy-efficient blockchain and cryptocurrency infrastructure through quantum-class laser-based computing. The company was founded in 1989 and is headquartered in New York, NY.

QCLS
Q/C Technologies Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest QCLS News

QCLSQ/C Technologies Inc.